AIM CONCEPT INTEGRATION
Osteoarthritis, Rheumatoid Arthritis and Rheumatoid Pharmacotherapy
3rd Year MBBS • KMU Curriculum
Connect the joint pattern, pathological mechanism, diagnostic clues and major drug actions for rapid revision.
1. THE TOPIC IN ONE CONNECTED FLOW
Osteoarthritis and rheumatoid arthritis both cause chronic joint pain and reduced function, but they develop through different processes. Osteoarthritis begins with cartilage failure and mechanical remodeling, whereas rheumatoid arthritis begins with immune-mediated synovitis. Their mechanisms explain the contrasting joint patterns, radiological findings, treatment goals and risk of progressive disability.
Cause or Risk
Aging and mechanical stress in OA, or genetic susceptibility with environmental triggers in RA
Aging and mechanical stress in OA, or genetic susceptibility with environmental triggers in RA
→
Core Mechanism
Cartilage matrix failure in OA, or cytokine-driven chronic synovitis in RA
Cartilage matrix failure in OA, or cytokine-driven chronic synovitis in RA
→
Structural Change
Osteophytes and subchondral sclerosis in OA, or pannus, cartilage loss and marginal erosion in RA
Osteophytes and subchondral sclerosis in OA, or pannus, cartilage loss and marginal erosion in RA
→
Clinical Pattern
Use-related pain and brief stiffness in OA, or symmetrical inflammatory small-joint disease with prolonged morning stiffness in RA
Use-related pain and brief stiffness in OA, or symmetrical inflammatory small-joint disease with prolonged morning stiffness in RA
→
Diagnostic Clue
Non-uniform joint-space loss and osteophytes suggest OA; autoantibodies, uniform narrowing and marginal erosions support RA
Non-uniform joint-space loss and osteophytes suggest OA; autoantibodies, uniform narrowing and marginal erosions support RA
→
Treatment Action
NSAIDs reduce symptoms; methotrexate and other DMARDs suppress RA activity and limit structural progression
NSAIDs reduce symptoms; methotrexate and other DMARDs suppress RA activity and limit structural progression
→
Outcome
Function may be preserved, or progressive cartilage damage, deformity and disability may develop
Function may be preserved, or progressive cartilage damage, deformity and disability may develop
2. KEY CLINICAL CONNECTIONS
Mechanical Joint Pattern
Pain worsened by use with brief stiffness
↓
Cartilage loss with subchondral remodeling
↓
Crepitus, bony enlargement, osteophytes and restricted movement
↓
Interpretation: Osteoarthritis
Inflammatory Joint Pattern
Prolonged morning stiffness with symmetrical MCP, PIP and wrist swelling
↓
Persistent immune-mediated synovitis
↓
Pannus formation, uniform cartilage loss and marginal erosions
↓
Interpretation: Rheumatoid arthritis
Methotrexate and Patient Safety
Weekly conventional DMARD therapy
↓
Anti-inflammatory adenosine effect with folate-pathway inhibition
↓
Reduced RA activity but possible marrow, hepatic, mucosal or pulmonary toxicity
↓
Action: CBC, hepatic and renal monitoring with clear counselling and teach-back
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Cartilage loss → subchondral sclerosis and osteophytes → mechanical pain, crepitus and restricted movement in osteoarthritis.
⭐ Cytokine-driven synovitis → pannus formation and RANKL-mediated osteoclast activity → cartilage destruction and marginal erosions in rheumatoid arthritis.
Use-related pain, brief stiffness and DIP bony nodes → osteoarthritis; prolonged morning stiffness with symmetrical MCP and PIP synovitis → rheumatoid arthritis.
Non-uniform joint-space narrowing with osteophytes → OA; periarticular osteopenia, uniform narrowing and marginal erosions → RA.
⭐ NSAID cyclooxygenase inhibition → reduced pain and stiffness, but it does not suppress the autoimmune process or prevent RA erosions.
⭐ Methotrexate → reduced inflammatory disease activity and structural progression, but weekly dosing and CBC, hepatic and renal monitoring are essential.
Biological or targeted immune suppression → control of resistant disease, but also increased risk of serious or reactivated infection.
Persistent joint destruction → deformity, reduced movement and disability; early disease control and clear patient instructions help preserve function.
AIM Exam Trap:
A positive rheumatoid factor supports rheumatoid arthritis but does not diagnose it alone. A negative result also does not exclude rheumatoid arthritis when the inflammatory clinical pattern is strongly suggestive.
A positive rheumatoid factor supports rheumatoid arthritis but does not diagnose it alone. A negative result also does not exclude rheumatoid arthritis when the inflammatory clinical pattern is strongly suggestive.